title: Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.
abstract: Genotypic antiretroviral testing is now widely used for the management of patients who are undergoing antiretroviral therapy for human immunodeficiency virus infection. The assays are complex, and there is considerable potential for variation between laboratories. Informative and ongoing quality assessment programs (QAPs) which address all aspects of testing are required. The panel distribution of clinical material is a critical component of QAPs. We report on the results and data from a recent panel. Four cryopreserved plasma samples from treated donors were distributed to nine laboratories. Three laboratories performed testing by commercial assays, and six laboratories used in-house assays, with one laboratory reporting results from two in-house assays. There was complete concordance between results for 95.9% of the nucleotide sequence and 94.5% of the amino acid sequence. Despite this overall high level of concordance, the degree of concordance at drug resistance mutation (DRM) sites when DRMs were present was considerably less (38% of DRM sites). Consequently, only 3 of the 10 methods reported 100% of DRMs as present. This elevated discrepancy rate is almost certainly a result of variability in the identification of mixtures of nucleotides (mixtures) at any site within the sequence. In addition, laboratories differed in the number of codons in the reverse transcriptase gene that were sequenced and their ability to amplify all samples. This panel distribution demonstrated a requirement for laboratory participation in ongoing QAPs and the optimization of assays with standards that contain mixtures.
authors.affiliation: Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth 6000, Western Australia, Australia. David.Sayer@health.wa.gov.au
authors.forename: D C
authors.initials: DC
authors.lastname: Sayer
authors.forename: S
authors.initials: S
authors.lastname: Land
authors.forename: L
authors.initials: L
authors.lastname: Gizzarelli
authors.forename: M
authors.initials: M
authors.lastname: French
authors.forename: G
authors.initials: G
authors.lastname: Hales
authors.forename: S
authors.initials: S
authors.lastname: Emery
authors.forename: F T
authors.initials: FT
authors.lastname: Christiansen
authors.forename: E M
authors.initials: EM
authors.lastname: Dax
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D004784:Environmental Monitoring; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D009154:Mutation; D017422:Sequence Analysis, DNA
chemical_list: D019380:Anti-HIV Agents; D054303:HIV Reverse Transcriptase